CNTA
Centessa Pharmaceuticals plc
Latest Form 4:Sale—byMedicxi Ventures Management (Jersey) Ltd (10% Owner) · filed Jun 24, 2026
Centessa Pharmaceuticals plc (CNTA) has 41 SEC Form 4 filings (89 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jun 24, 2026.
The most active filer is Chief Legal Officer HUSSAIN IQBAL J with 7 filings. Insiders have net sold $10.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Mario Alberto Accardi
- Employees:77
- HQ:Altrincham, GB
- IPO:2021-05-28
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$16.6M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Medicxi Ventures Management (Jersey) LtdFirst filing | 10% Owner | Sale | 19,963,157 | — | Jun 24 | SEC ↗ |
INDEX VENTURES LIFE VI (JERSEY) L.P.First filing | 10% Owner | Sale | 9,961,789 | — | Jun 24 | SEC ↗ |
| Chief People Officer | Sale | 41,076 | $1.2M | Mar 27 | SEC ↗ | |
| Chief Business Officer | Sale | 23,998 | $720K | Mar 26 | SEC ↗ | |
| Chief People Officer | Sale | 64,768 | $1.8M | Mar 18 | SEC ↗ | |
| Chief People Officer | Sale | 10,043 | $282K | Mar 18 | SEC ↗ | |
| Chief People Officer | Sale | 120,029 | $3.2M | Mar 16 | SEC ↗ | |
Weinhoff Gregory MFirst filing | Chief Business Officer | Sale | 73,196 | $1.9M | Mar 13 | SEC ↗ |
| Chief Legal Officer | Sale | 1,010 | $25K | Feb 3 | SEC ↗ | |
| Chief Legal Officer | Sale | 38,951 | $980K | Feb 3 | SEC ↗ | |
| President, Orexin Program | Sale | 10,000 | $288K | Dec 9 | SEC ↗ | |
| President, Orexin Program | Sale | 10,000 | $300K | Dec 8 | SEC ↗ | |
| General Counsel | Sale | 6,000 | $166K | Nov 18 | SEC ↗ | |
| Chief Technology & Quality Ofc | Sale | 40,000 | $1.1M | Nov 18 | SEC ↗ | |
| Chief Technology & Quality Ofc | Sale | 40,000 | $1.0M | Nov 13 | SEC ↗ | |
| President, Orexin Program | Sale | 8,000 | $200K | Oct 27 | SEC ↗ | |
| General Counsel | Sale | 6,000 | $134K | Oct 16 | SEC ↗ | |
| Chief Technology & Quality Ofc | Sale | 35,000 | $840K | Sep 24 | SEC ↗ | |
| President, Orexin Program | Sale | 8,172 | $175K | Sep 16 | SEC ↗ | |
| General Counsel | Sale | 6,000 | $131K | Sep 15 | SEC ↗ | |
Bush Tia LFirst filing | Chief Technology & Quality Ofc | Sale | 24,792 | $496K | Sep 11 | SEC ↗ |
Bush Tia LFirst filing | Chief Technology & Quality Ofc | Sale | 25,000 | $550K | Sep 11 | SEC ↗ |
HUSSAIN IQBAL JFirst filing | General Counsel | Sale | 20,000 | $400K | Sep 11 | SEC ↗ |
HUSSAIN IQBAL JFirst filing | General Counsel | Sale | 20,000 | $440K | Sep 11 | SEC ↗ |
Accardi Mario AlbertoFirst filing | President, Orexin Program | Sale | 7,000 | $140K | Sep 11 | SEC ↗ |
Related companies
Centessa Pharmaceuticals plc is in the Healthcare sector.